LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Regulation FD Disclosure

Item 7.01 Regulation FD.

On December18, 2016, Loxo Oncology,Inc. (Loxo Oncology) issued a
press release announcing the presentation of updated clinical
data for Loxo Oncologys ongoing LOXO-101 Phase 1 trial as
reported by study investigators at the 2016 European Society for
Medical Oncology Asia Congress in Singapore. A copy of the press
release is furnished as Exhibit99.1 to this report and
incorporated herein by reference.A copy of the slides presented
by the study investigators are furnished as Exhibit99.2 to this
report and incorporated herein by reference.

On December19, 2016, Loxo Oncology issued a press release
announcing program updates and an investor conference call. A
copy of the press release is furnished as Exhibit99.3 to this
report and incorporated herein by reference.A copy of the slides
presented during the investor conference call are furnished as
Exhibit99.4 to this report and incorporated herein by reference.

The information furnished with this report, including
Exhibit99.1, Exhibit99.2, Exhibit99.3 and Exhibit99.4, shall not
be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (Exchange Act), or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference into any other filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d)Exhibits.

About LOXO ONCOLOGY, INC. (NASDAQ:LOXO)

Loxo Oncology, Inc. is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer. Its pipeline includes LOXO-101, LOXO-195, Rearranged During Transfection (RET) Program and Fibroblast Growth Factor Receptor (FGFR) program. LOXO-101 is a selective inhibitor of tropomyosin receptor kinases (TRK) for the treatment of patients with soft tissue sarcoma. LOXO-195 is a selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving LOXO-101 or multikinase inhibitors with anti-TRK activity. It has designed a series of RET inhibitors that optimize on-target potency for RET gene fusions, mutations and clinically-identified resistance mutations. It is designing FGFR1-sparing FGFR inhibitor.

LOXO ONCOLOGY, INC. (NASDAQ:LOXO) Recent Trading Information

LOXO ONCOLOGY, INC. (NASDAQ:LOXO) closed its last trading session up +6.95 at 33.86 with 2,465,724 shares trading hands.